Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 20, 2017
Pharmacy Choice - Pharmaceutical News - Analyst Activity Noble Financial Reiterates Buy on Eyegate Pharmaceuticals (NASDAQ:EYEG) - August 20, 2017

Pharmacy News Article

 5/19/17 - Analyst Activity Noble Financial Reiterates Buy on Eyegate Pharmaceuticals (NASDAQ:EYEG)

Analyst Ratings For Eyegate Pharmaceuticals (NASDAQ:EYEG)

Today, Noble Financial reiterated its Buy rating on Eyegate Pharmaceuticals (NASDAQ:EYEG).

There are 1 hold rating, 4 buy ratings on the stock.

The current consensus rating on Eyegate Pharmaceuticals (NASDAQ:EYEG) is Buy (Score: 2.80) with a consensus target price of $9.00 per share, a potential 399.97% upside.

Some recent analyst ratings include

  • 5/19/2017-Noble Financial Reiterated Rating of Buy.
  • 12/6/2016-Chardan Capital Reiterated Rating of Buy.
  • 12/1/2016-Rodman & Renshaw Reiterated Rating of Buy.
  • 6/28/2016-Maxim Group Reiterated Rating of Hold.

Dividend information for Eyegate Pharmaceuticals (NASDAQ:EYEG)

.
Recent Insider Trading Activity For Eyegate Pharmaceuticals (NASDAQ:EYEG)
Eyegate Pharmaceuticals (NASDAQ:EYEG) has insider ownership of 26.50% and institutional ownership of 6.43%.

  • On 3/6/2017 Morton Goldberg, Director, sold 8,919 with an average share price of $3.00 per share and the total transaction amounting to $26,757.00. View SEC Filing
  • On 9/15/2016 Stephen From, Insider, bought 15,000 with an average share price of $1.49 per share and the total transaction amounting to $22,350.00. View SEC Filing
  • On 6/15/2016 Morton Goldberg, Director, sold 15,000 with an average share price of $3.16 per share and the total transaction amounting to $47,400.00. View SEC Filing
  • On 6/10/2016 Ventech Capital Ii, Major Shareholder, sold 28,600 with an average share price of $3.04 per share and the total transaction amounting to $86,944.00. View SEC Filing
  • On 6/8/2016 Ventech Capital Ii, Major Shareholder, sold 29,400 with an average share price of $3.25 per share and the total transaction amounting to $95,550.00. View SEC Filing
  • On 6/7/2016 Morton Goldberg, Director, sold 10,939 with an average share price of $3.31 per share and the total transaction amounting to $36,208.09. View SEC Filing
  • On 2/19/2015 (Innoven Partenaires S.A. Ipsa, Major Shareholder, bought 366,667 with an average share price of $6.00 per share and the total transaction amounting to $2,200,002.00. View SEC Filing

About Eyegate Pharmaceuticals (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Recent Trading Activity for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Shares of Eyegate Pharmaceuticals closed the previous trading session at 1.80 down -0.10 -5.26% with 96,677 shares trading hands.

The post Analyst Activity Noble Financial Reiterates Buy on Eyegate Pharmaceuticals (NASDAQ:EYEG) appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Aug 21: An Integrative Approach to Managing Arthritis
Aug 22: Men's Health
Aug 23: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Aug 24: Treatment of Parkinson's Disease and Comorbid Conditions
Aug 25: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415